HEALTHEQUITY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HEALTHEQUITY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $60.44M | Mar 28, 2018 |
| FY2018 | Oct 31, 2017 | $56.79M | Mar 28, 2018 |
| FY2018 | Jul 31, 2017 | $56.88M | Mar 28, 2018 |
| FY2018 | Apr 30, 2017 | $55.42M | Mar 28, 2018 |
| FY2018 | Jan 31, 2017 | $46.81M | Mar 28, 2018 |
| FY2018 | Oct 31, 2016 | $43.36M | Mar 28, 2018 |
| FY2018 | Jul 31, 2016 | $44.19M | Mar 28, 2018 |
| FY2018 | Apr 30, 2016 | $44.01M | Mar 28, 2018 |
| FY2017 | Jan 31, 2016 | $35.89M | Mar 30, 2017 |
| FY2017 | Oct 31, 2015 | $30.56M | Mar 30, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.31B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.20B | Mar 17, 2026 |
| FY2024 | Jan 31, 2024 | $262.39M | Mar 22, 2024 |
| FY2024 | Oct 31, 2023 | $249.22M | Mar 22, 2024 |
| FY2024 | Jul 31, 2023 | $243.55M | Mar 22, 2024 |
| FY2024 | Apr 30, 2023 | $244.43M | Mar 22, 2024 |
| FY2024 | Jan 31, 2023 | $233.84M | Mar 22, 2024 |
| FY2024 | Oct 31, 2022 | $216.09M | Mar 22, 2024 |
| FY2024 | Jul 31, 2022 | $206.14M | Mar 22, 2024 |
| FY2024 | Apr 30, 2022 | $205.68M | Mar 22, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $913.12M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $777.26M | Mar 17, 2026 |
| FY2024 | Jan 31, 2024 | $163.32M | Mar 22, 2024 |
| FY2024 | Oct 31, 2023 | $159.18M | Mar 22, 2024 |
| FY2024 | Jul 31, 2023 | $151.67M | Mar 22, 2024 |
| FY2024 | Apr 30, 2023 | $148.47M | Mar 22, 2024 |
| FY2024 | Jan 31, 2023 | $134.77M | Mar 22, 2024 |
| FY2024 | Oct 31, 2022 | $127.32M | Mar 22, 2024 |
| FY2024 | Jul 31, 2022 | $118.25M | Mar 22, 2024 |
| FY2024 | Apr 30, 2022 | $111.60M | Mar 22, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $215.20M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $96.70M | Mar 17, 2026 |
| FY2024 | Jan 31, 2024 | $26.36M | Mar 22, 2024 |
| FY2024 | Oct 31, 2023 | $14.67M | Mar 22, 2024 |
| FY2024 | Jul 31, 2023 | $10.58M | Mar 22, 2024 |
| FY2024 | Apr 30, 2023 | $4.09M | Mar 22, 2024 |
| FY2024 | Jan 31, 2023 | ($209.0K) | Mar 22, 2024 |
| FY2024 | Oct 31, 2022 | ($1.64M) | Mar 22, 2024 |
| FY2024 | Jul 31, 2022 | ($10.65M) | Mar 22, 2024 |
| FY2024 | Apr 30, 2022 | ($13.64M) | Mar 22, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $322.46M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $162.33M | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $117.70M | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | $9.06M | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | ($24.24M) | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | $34.01M | Mar 30, 2023 |
| FY2022 | Jan 31, 2020 | $77.01M | Mar 31, 2022 |
| FY2021 | Jan 31, 2019 | $77.67M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $54.42M | Mar 31, 2020 |
| FY2019 | Jan 31, 2017 | $41.21M | Mar 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $262.51M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $239.51M | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $218.81M | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | $193.38M | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | $157.36M | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | $124.81M | Mar 30, 2023 |
| FY2022 | Jan 31, 2020 | $77.58M | Mar 31, 2022 |
| FY2021 | Jan 31, 2019 | $35.06M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $27.39M | Mar 31, 2020 |
| FY2019 | Jan 31, 2017 | $22.38M | Mar 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $457.09M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $339.86M | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $242.83M | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | $150.65M | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | $141.00M | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | $181.62M | Mar 30, 2023 |
| FY2022 | Jan 31, 2020 | $105.01M | Mar 31, 2022 |
| FY2021 | Jan 31, 2019 | $113.42M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $81.70M | Mar 31, 2020 |
| FY2019 | Jan 31, 2017 | $45.59M | Mar 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.97M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $2.08M | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $1.69M | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | $3.37M | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | $8.91M | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | $13.09M | Mar 30, 2023 |
| FY2022 | Jan 31, 2020 | $7.29M | Mar 31, 2022 |
| FY2021 | Jan 31, 2019 | $3.87M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $5.46M | Mar 31, 2020 |
| FY2019 | Jan 31, 2017 | $3.65M | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $3.38B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $3.45B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $3.16B | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $3.09B | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $3.11B | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $2.71B | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $2.56B | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $510.02M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $369.16M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | $279.14M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.27B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.33B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $1.13B | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $1.19B | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $1.25B | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $1.33B | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $1.53B | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $32.94M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $22.89M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | $17.20M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $2.11B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $2.11B | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $2.04B | Mar 17, 2026 |
| FY2026 | Jan 31, 2023 | $1.90B | Mar 17, 2026 |
| FY2025 | Jan 31, 2022 | $1.85B | Mar 18, 2025 |
| FY2024 | Jan 31, 2021 | $1.38B | Mar 22, 2024 |
| FY2023 | Jan 31, 2020 | $1.03B | Mar 30, 2023 |
| FY2022 | Jan 31, 2019 | $477.08M | Mar 31, 2022 |
| FY2021 | Jan 31, 2018 | $346.27M | Mar 31, 2021 |
| FY2020 | Jan 31, 2017 | $261.94M | Mar 31, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.65B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.65B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $1.65B | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $1.65B | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $1.65B | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $1.33B | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $1.33B | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $4.65M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $4.65M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | $4.65M | Mar 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $195.91M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $209.27M | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $205.63M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $149.92M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $176.06M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $220.35M | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $211.51M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $171.85M | Mar 31, 2020 |
| FY2019 | Feb 1, 2018 | $98.31M | Mar 28, 2019 |
| FY2019 | Jan 31, 2018 | $85.30M | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $318.93M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $295.95M | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $403.98M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $254.27M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $225.41M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $328.80M | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $191.73M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $361.48M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $199.47M | Mar 28, 2019 |
| FY2019 | Jan 31, 2017 | $139.95M | Mar 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $957.38M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.06B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $874.97M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $925.34M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $930.83M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $986.72M | Mar 31, 2022 |
| FY2020 | Jan 31, 2020 | $1.22B | Mar 31, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Mar 30, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 31, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Mar 30, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 31, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 85.01M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | 86.54M | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | 86.13M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | 84.76M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | 83.78M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | 77.17M | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | 71.05M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | 62.45M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | 60.83M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | 59.54M | Mar 28, 2018 |